Basappa et al. / Bioorg. Med. Chem. 17 (2009) 4928–4934
4933
(d, 2H, Ar-H), 6.97 (m, 1H, Ar-H), 5.77–5.86 (m, 1H, @CH), 5.16–
5.20 (m, 2H, CH2@), 4.1 (d, 2H, –CH2), 3.65 (s, 2H, –CH2), 2.46–
2.51 (m, 2H, –CH–), 2.17–2.20 (m, 4H, –CH2–), 1.77–1.82 (m, 4H,
–CH2–). MS (ESI + ion): m/z = 344.1. IR (KBr, cmꢁ1): 3350, 1660.
containing 66
Incubated the plates for 48 h at 37 °C under 5% CO2. After the indi-
cated time, 5 L of TetraColor One was added to each well and the
mixture was incubated for an additional 2 h. The viability of cells
treated with DMBO was measured using TetraColor One.14 Absor-
bance at 450 nm was monitored and the percentage viability of
the cells was calculated. The % inhibition of the proliferation of nor-
mal or tumor cells by the hydantoin derivatives was presented.
Results are reported as the average four replicates.
lg/mL concentrations of hydantoin derivatives.
l
5.6.6. Synthesis of 10-allyl-8-(3,4-difluorobenzyl)-8-azaspiro
[bicyclo[3.2.1]octane-3,40-imidazolidine]-20,50-dione (7f)
The general experimental procedure described above afforded
7f, the product obtained (0.19 g) was white crystalline solid from
10-allyl-8-azaspiro[bicyclo[3.2.1]octane-3,40-imidazolidine]-20,50-
dione 5b (0.20 g, 0.85 mmol), 4-(bromomethyl)-1,2-difluoroben-
zene (0.17 g, 0.85 mmol), and K2CO3 (0.58 g, 4.25 mmol). 1H NMR
(CDCl3, 400 MHz) d: 8.52 (s, 1H, –NH), 7.32–7.39 (m, 2H, Ar-H),
7.17–7.2 (m, 1H, Ar-H), 5.72–5.79 (m, 1H, @CH), 4.93–5.08 (m,
2H, CH2@), 3.94 (d, 2H, –CH2), 3.52 (s, 2H, –CH2), 2.44–2.49 (m,
2H, –CH–), 2.15–2.2 (m, 4H, –CH2–), 1.92–1.98 (m, 4H, –CH2–).
MS (ESI + ion): m/z = 362.2. IR (KBr, cmꢁ1): 3371, 1658.
5.6.11. Real-time proliferation assay
LM8G7 (10,000 cells/well) were seeded in ACEA0s 96X e-plateTM
in a final volume of 150
when the cells were in the log growth phase, they were incubated
with 150 L of medium containing various concentrations of com-
l
L.11 Approximately, 24 h after seeding,
l
pound 7h or 7i or DMSO as a solvent control. The effect of the com-
pounds on the proliferation of LM8G7 cells was monitored
dynamically for every 10 min. The cell index (quantitative mea-
surement of cells) against the time was plotted. The IC50 values
were calculated from concentration–response curves by a non-lin-
ear regression analysis using Prism software (GraphPad Software,
San Diego, CA).
5.6.7. Synthesis of 8-(4-fluorobenzyl)-10-(4-(methylsulfonyl)
benzyl)-8-azaspiro[bicyclo [3.2.1]octane-3,40-imidazolidine]-
20,50-dione (7g)
The general experimental procedure described above afforded 7g,
the product obtained (0.20 g) was off-white crystalline solid from
10-(4-(methylsulfonyl)benzyl)-8-azaspiro[bicyclo[3.2.1]octane-3,40-
imidazolidine]-20,50-dione 5c (0.20 g, 0.55 mmol), 1-(bromomethyl)-
4-fluorobenzene (0.10 g, 0.55 mmol), and K2CO3 (0.38 g, 2.75 mmol).
1H NMR (CDCl3, 400 MHz) d: 8.60 (s, 1H, –NH), 7.91 (d, 2H, Ar-H), 7.55
(d, 2H, Ar-H), 7.27–7.38 (m, 2H, Ar-H), 7.02 (t, 2H, Ar-H), 4.72 (s, 2H,
–CH2–), 3.60 (s, 2H, –CH2–), 3.04 (s, 3H, –CH3), 2.44–2.47 (m, 2H,
–CH–), 2.17–2.19 (m, 4H, –CH2–), 1.74–1.80 (m, 4H, –CH2–). MS
(ESI + ion): m/z = 472.1. IR (KBr, cmꢁ1): 3357, 1650, 1340, 1285.
5.6.12. In vitro angiogenesis assay
MatrigelTM (ECM 625, Chemicon) was added to a 24-well plate
in a final volume of 100 lL and allowed to solidify at 37 °C for
30 min. Single cell suspensions (100 lL) of UV$2 were seeded at
a density of 4 ꢀ 105 cells/mL, to the MatrigelTM coated well, with
or without compound 7i (50 lM) and VEGF (2 ng/mL). After 18 h
of culture, the reorganization of the sub-confluent monolayer of
UV$2 cells in 3-dimensional MatrigelTM was monitored and photo-
graphed in a light microscope attached to a 3CCD camera (Olym-
pus, FX380-model, JAPAN).
5.6.8. Synthesis of 8-(3-fluorobenzyl)-10-(4-(methylsulfonyl)
benzyl)-8-azaspiro[bicyclo [3.2.1]octane-3,40-imidazolidine]-
20,50-dione (7h)
5.6.13. VEGF quantification assay
The general experimental procedure described above afforded
7h, the product obtained (0.19 g) was off-white crystalline solid
LM8G7 (1 ꢀ 106) cells were seeded into a 6-well plates and
incubated overnight. After 24 h, the media was replaced with fresh
from
10-(4-(methylsulfonyl)benzyl)-8-azaspiro[bicyclo[3.2.1]
serum-free medium containing 56 lM, 102 lM, and 204 lM of
octane-3,40-imidazolidine]-20,50-dione 5c (0.20 g, 0.55 mmol), 1-
(bromomethyl)-3-fluorobenzene (0.10 g, 0.55 mmol), and K2CO3
(0.38 g, 2.75 mmol). 1H NMR (CDCl3, 400 MHz) d: 8.66 (s, 1H,
–NH), 7.89 (d, 2H, Ar-H), 7.45 (d, 2H, Ar-H), 7.32–7.38 (m, 1H, Ar-
H), 7.19 (t, 2H, Ar-H), 7.07 (t, 1H, Ar-H), 4.64 (s, 2H, –CH2–), 3.57 (s,
2H, –CH2–), 3.15 (s, 3H, –CH3), 2.49–2.50 (m, 2H, –CH–), 2.19–2.23
(m, 4H, –CH2–), 1.93–2.0 (m, 4H, –CH2–). MS (ESI + ion): m/z = 472.
IR (KBr, cmꢁ1): 3355, 1648, 1333, 1280.
compound 7i. The cells were further incubated for 48 h at 37 °C.
The cell supernatant was collected, centrifuged at 5000 rpm for
5 min at 4 °C and the protein concentrations were determined by
BCA (bicinchoninic acid) assay kit (Thermo Fisher Scientific Inc.
USA).15 The quantification of the mouse VEGF was done using
the Immuno Assay Kit (Quantikine, R&D systems). Briefly, the
known amount of recombinant VEGF as standard and the samples
to be tested were added to a 96-well microplate, which was pre-
coated with the polyclonal antibody specific for mouse VEGF and
incubated for 2 h. The bound VEGF was detected by adding horse-
radish peroxidase conjugated polyclonal antibody against mouse
VEGF. After 2 h, the substrate chromogen was added and allowed
to react for 30 min with the peroxidase conjugate, the reaction
was stopped and the VEGF content was quantified in a micro-plate
reader at 450 nm (BIORAD, Model 680). The decrease in the
amount of VEGF secretion by the compound 7i was presented.
5.6.9. Synthesis of 8-(3,4-difluorobenzyl)-10-(4-(methylsulfonyl)
benzyl)-8-azaspiro[bicyclo [3.2.1]octane-3,40-imidazolidine]-
20,50-dione (7i)
The general experimental procedure described above afforded 7i,
the product obtained (0.195 g) was off-white crystalline solid from
10-(4-(methylsulfonyl)benzyl)-8-azaspiro[bicyclo[3.2.1]octane-3,40-
imidazolidine]-20,50-dione 5c (0.20 g, 0.55 mmol), 4-(bromomethyl)-
1,2-difluorobenzene (0.11 g, 0.55 mmol), and K2CO3 (0.38 g,
2.75 mmol). 1H NMR (CDCl3, 400 MHz) d: 8.64 (s, 1H, –NH), 7.87 (d,
2H, Ar-H), 7.46 (d, 2H, Ar-H), 7.30–7.36 (m, 1H, Ar-H), 7.19 (t, 1H,
Ar-H), 7.04 (t, 1H, Ar-H), 4.60 (s, 2H, –CH2–), 3.55 (s, 2H, –CH2–),
3.17 (s, 3H, –CH3), 2.45–2.50 (m, 2H, –CH–), 2.19–2.25 (m, 4H,
–CH2–), 1.95–2.0 (m, 4H, –CH2–). MS (ESI + ion): m/z = 490. IR (KBr,
cmꢁ1): 3351, 1653, 1340, 1284.
Acknowledgements
This work was supported in part by the INSA (Indian National
Science Academy)-JSPS (Japan Society for the Promotion of Sci-
ence) program between India (to K.S.R.) and Japan (to K.S.). Profes-
sor K.S.R. grateful to UGC, Govt. of India for financial support under
the project UGC-SAP (Phase I) DRS Programme DV4/375/2004–05
and one of the authors, Basappa thanks JSPS, Japan for the award
of JSPS Postdoctoral fellowship. We thank Prof. M. Miyasaka, Dr.
K. N. Sugahara and Dr. C. M. Lee for providing the LM8 and
LM8G7 cells.
5.6.10. In vitro cell proliferation assay
SKOV-3, OVSAHO, LM8, LM8G7, and UV$2 cells were seeded at a
density of 15,000 cells/well in a 96-well plate and incubated over-
night at 37 °C. The medium was changed to the new medium